Prognostic relevance of treatment deviations in children with relapsed acute lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study
Open Access
- 11 December 2024
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 39 (2) , 337-345
Abstract
Relapsed Acute Lymphoblastic Leukemia (ALL) is among the most common causes of cancer-associated deaths in children. However, little is known about the implications of deviations from ALL treatment protocols on survival rates. The present study elucidates the various characteristics of treatment deviations in children with relapsed ALL included in the ALL-REZ BFM 2002 (i.e., Relapse Berlin-Frankfurt- Münster) trial and determines their prognostic relevance for relapse and death rates. Among 687 patients, 100 were identified with treatment deviations, further classified, and examined by occurrence time, cause and type. Protocol deviation was considered a time-dependent variable and its impact on Disease Free Survival (DFS) and Overall Survival (OS) was examined using the time-dependent model Mantel Byar. Five years after the relapse diagnosis, deviations were significantly related to both inferior DFS (38%) and OS (57%) rates compared to protocol conformed treatment (DFS = 61%; OS = 70%, P < 0.001). Based on multivariate analyses, protocol deviation proved to be an independent adverse prognostic factor of DFS. Moreover, deviations triggered by chemotherapy-induced toxicity were associated with a higher relapse rate compared to deviations due to insufficient response. Therefore, to avoid impairment of results by deviations, future clinical trials, and treatment strategies should focus on less toxic treatments and stricter protocol compliance.Keywords
Funding Information
- Deutsche Kinderkrebsstiftung (DKS 2012.21, DKS 2012.21)
- KINDerLEBEN Verein zur Förderung der Klinik für krebskranke Kinder e.V. Berlin = PhD Scholarship for one year
This publication has 44 references indexed in Scilit:
- Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphomaEuropean Journal of Cancer, 2022
- Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trialsEuropean Journal of Cancer, 2021
- Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic LeukemiaJAMA, 2021
- Quality and safety in pediatric hematology/oncologyPediatric Blood & Cancer, 2014
- Impact of immortal person-time and time scale in comparative effectiveness research for medical devices: a case for implantable cardioverter-defibrillatorsJournal of Clinical Epidemiology, 2013
- Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia – Long-term results of trial ALL-REZ BFM P95/96European Journal of Cancer, 2013
- Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group studyLeukemia, 2008
- Competing risk analysis using R: an easy guide for cliniciansBone Marrow Transplantation, 2007
- Survival plots of time-to-event outcomes in clinical trials: good practice and pitfallsThe Lancet, 2002
- Survival after relapse in childhood acute lymphoblastic leukemiaCancer, 1998